Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment

Curemark Enrolls First Patients in Phase III Clinical Trials for Autism
Treatment

RYE, N.Y., Oct. 14 /PRNewswire/ -- Curemark, LLC, a drug research and
development company focused on the treatment of neurological diseases,
announced that it has enrolled the first patients in Phase III clinical trials
for its autism treatment, CM-AT. The first clinical trial patients have been
enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical
trial sites with a total 170 children across the country.

CM-AT is based on research by Curemark founder and CEO Dr. Joan Fallon that
showed enzyme deficiencies in autistic children, resulting in an inability to
digest protein. The inability to digest protein affects the production of
amino acids, the building blocks of chemicals essential for brain function.

"We are very excited to be enrolling our first children in the Phase III
trials for CM-AT. Our progress with the clinical trials culminates years of
research resulting in the breakthrough discovery of this therapy for children
with autism," Fallon said. "We're hopeful that CM-AT will be one of the first
therapies to address the underlying physiology of autism, rather than just
treat its symptoms."

A new study released in early October by the U.S. Centers for Disease Control
(CDC) showed that the number of children affected by autism is much higher
than originally thought. According to the study, autism affects 1 in 91
children and about 1 in 58 boys, totaling an estimated 673,000 or
approximately 1% of all children in the U.S.

For information on participating in the trials, log on to
www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment
of neurological and other diseases, especially those with dysautonomic
components, by addressing certain key gastrointestinal/pancreatic secretory
deficiencies. The company's initial products are based upon breakthrough
observations by its founder, Dr. Joan Fallon, which revealed a lack of protein
digestion in children with autism and ADHD. To learn more about our innovative
science, visit www.curemark.com

Safe Harbor Statement
This news release contains forward-looking statements that involve risks and
uncertainties that could cause our actual results and experiences to differ
materially from anticipated results and expectations expressed in such
forward-looking statement. These forward-looking statements include, without
limitation, statements regarding the mechanism of action of CM-AT, its
potential advantages, its potential for use in treating autism, as well as the
timing, progress and anticipated results of the clinical development and
regulatory processes concerning CM-AT. These statements are based on our
current beliefs and expectations as to such future outcomes, and are subject
to known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made. Factors
that might cause such a material difference include, among others, risks that
the results of clinical trials will not support our claims or beliefs
concerning the effectiveness of CM-AT, our ability to finance our development
of CM-AT, regulatory risks, and our reliance on third party researchers and
other collaborators. We assume no obligation to update these statements,
except as required by law.

SOURCE Curemark, LLC

Michelle Manoff, Rubenstein Public Relations, +1-212-843-8051,
mmanoff@rubensteinpr.com, or Dr. Joan Fallon, Curemark LLC, +1-914-925-3450,
joan.fallon@curemark.com